May 31, 2012 (Atlanta) — Dr. Rodolfo Bordoni of Georgia Cancer Specialists (GCS)—a Top 10 private cancer practice in the U.S.— published an article in the May issue of the journal Community Oncology on the incidence of febrile neutropenia (FN) in women receiving docetaxel plus cyclophosphamide (TC) as adjuvant therapy for early-stage breast cancer.
The article, based on original research at GCS, was co-authored by Sally Taylor Haislip, RPh, James Walter Gilmore Jr, PharmD, and Joyce Sharpe, RN, OCN, of GCS, and Drs. Mi Rim Choi and Esteban Abella of Amgen Inc., Thousand Oaks, California.
The research incorporated the largest community-based retrospective study to evaluate FN incidence in patients with early-stage breast cancer (ESBC) who are treated with TC.
Researchers analyzed electronic medical record data from ESBC patients receiving TC. The analysis included 662 women, the median age was 55 years, and the median number of cycles of TC received was four.
Febrile neutropenia is a fever related to an abnormally low count of neutrophils, white blood cells that help an individual’s immune system fight off infections, particularly of bacteria and fungi.
The journal Community Oncology concentrates particularly on original research, rare cancers in the community setting, quality of care in community oncology, end-of-life care, community practice guidelines, practice management and reimbursement issues, and news from Washington and the US Food and Drug Administration.
Georgia Cancer Specialists is a Top 10 private cancer practice in the U.S. and a leader in advanced cancer treatment and research. The practice supports more than 200,000 patient visits each year. GCS offers community-based medical oncology and hematology services and is the first private oncology practice to also provide a full range of support services for patients in Georgia, including wellness counseling and home health coordination. The GCS research department, whose focus is bringing targeted cancer therapy to communities, is the first in Georgia to offer Phase I clinical trials, the most novel cancer therapies available. GCS has 27 offices, 44 physicians, and more than 500 support staff members located in Metro Atlanta, and North and Central Georgia. Georgia Cancer Specialists can be found on the web at www.gacancer.com GCS is The Cancer Answer.